Jacksonville Wealth Management LLC Invests $231,000 in Eli Lilly and Company $LLY

Jacksonville Wealth Management LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 296 shares of the company’s stock, valued at approximately $231,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at $27,000. Blume Capital Management Inc. boosted its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new position in Eli Lilly and Company in the second quarter valued at $35,000. TD Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in shares of Eli Lilly and Company during the first quarter worth about $55,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $886.00 to $1,104.00 in a report on Monday. Finally, HSBC increased their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $999.32.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,022.00 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a 50 day simple moving average of $820.93 and a 200-day simple moving average of $779.85. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,032.95. The stock has a market capitalization of $966.19 billion, a PE ratio of 66.80, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.